

Olerup SSP® HLA-B*39

Product number: 101.566-12/04 – including *Taq* pol.
 101.566-12u/04u – without *Taq* pol.
Lot number: 6L3
Expiry date: 2024-11-01
Number of tests: 12 tests – Product No. 101.566-12/12u
 4 tests – Product No. 101.566-04/04u
Number of wells per test: 44+1

Changes compared to the previous HLA-B*39 Lot (2H5):

| Well | 5'-primer | 3'-primer | rationale |
|------|-----------|-----------|--|
| 5 | Added | - | 5'-primer added for the B*39:01:27 allele. |
| 7 | Modified | - | 5'-primer modified for reducing tendency of primer oligomer formation. |
| 19 | Modified | - | 5'-primer modified for improved yield. |
| 23 | Modified | - | 5'-primer modified for reducing tendency of primer oligomer formation. |

THE NUMBER OF WELLS is unchanged.

ALLELE COVERAGE:

B*39:01 to B*39:168 i.e. all the currently recognized HLA-B*39 alleles, will be amplified by the primers in the HLA-B*39 subtyping kit^{1,2}; www.ebi.ac.uk/imgt/hla, 2020-July-13 release 3.41.0.

The HLA-B*39 kit enables separation of the confirmed HLA-B*39 alleles as listed in the IMGT/HLA database 3.29.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources.

The HLA-B*39 kit also enables identification of many null and alternatively expressed alleles.

The following HLA-B*39 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

| Alleles | Primer mix | Alleles | Primer mix |
|--------------------|------------|-----------------|------------|
| B*39:01:05, 39:59 | 9 | B*39:41, 39:77 | 13 |
| B*39:19:02, 39:134 | 10 | B*39:62, 39:64 | 30 |
| B*39:25N, 39:44 | 17 | B*39:87N, 39:93 | 33 |
| B*39:26, 39:51 | 4 | | |

¹Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

101.566-12/04 – including *Taq* polymerase
101.566-12u/04u – without *Taq* polymerase

Lot No.: 6L3

²The following alleles will give rise to identical amplification patterns with the HLA-B*39 subtyping kit. These alleles can be distinguished by the HLA-B low resolution and/or the respective HLA-B kits.

| Alleles | Alleles |
|--|--|
| B*39:01:01:01, 39:01:01:03-39:01:01:14, 39:01:03:01-39:01:03:02, 39:01:06-39:01:08, 39:01:10-39:01:24, 39:01:28-39:01:29, 39:01:31-39:01:32, 39:65-39:67, 39:69, 39:71, 39:80-39:81, 39:84-39:85, 39:94, 39:100, 39:103, 39:111, 39:114-39:115, 39:117, 39:119, 39:121-39:123, 39:125, 39:130, 39:137-39:138, 39:142N, 39:146N, 39:148, 39:150Q-39:151, 39:153, 39:157N, 39:159-39:160, B*38:158 | B*39:82, 39:107, 39:136, 39:156, B*14:53 |
| B*39:05:01:01-39:05:03, 39:113, 39:118, 39:147N, 39:149, 39:161N, 39:163, 39:165, 39:167-39:168, B*38:157 | B*39:104, B*38:41 |
| B*39:09:01:01-39:09:04, 39:158, B*38:156 | |

RESOLUTION IN HLA-B*39 HOMO- AND HETEROZYGOTES:

Good.

INFLUENCE ON THE INTERPRETATION OF HLA-B*39 SUBTYPINGS BY NON-HLA-B*39 ALLELES:

None frequently occurring.

MODIFICATIONS MADE DUE TO COMMENTS FROM CUSTOMERS:

No comments received.